三一生物技术 plc 美股招股说明书（2026年6月18日版）

TRINITY BIOTECH PLC Secondary offering of up to33,752,429 American Depositary Shares This prospectus supplement updates and supplements the information contained in the prospectus dated June 16, 2026 (as may besupplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form F-1, withinformation contained in our Report on Form 6-K, which was filed with the Securities and Exchange Commission on June 18, 2026 The prospectus, as it may be amended or supplemented from time to time, relates to the offer and resale by the Selling Shareholdersfrom time to time of up to 675,048,580 Ordinary Shares, represented by up to 33,752,429 ADSs. Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol “TRIB.” The last reported sale price of ourADSs on June 17, 2026 was $0.5799. You should read the Prospectus, this prospectus supplement and any additional prospectus supplement or amendment carefully beforeyou invest in our securities. Our business and an investment in our ADSs involve significant risks. These risks are described under the caption “Risk Factors”beginning on page 4 of the Prospectus and any other risk factors contained in any applicable prospectus supplement and in the Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securitiesor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is June 18, 2026. FORM6-K For the month of June 2026 TRINITY BIOTECH PLC(Name of Registrant) IDA Business ParkBray, County. Wicklow, Ireland Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒Form 40-F☐ This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Form F-3 and (File Nos. 333-267160, 333-286020, 333-295842 and 333-280391). EXPLANATORY NOTE On June 16, 2026 the Company announced it had been awarded significant orders for over 2 million TrinScreen HIV tests. TheCompany also announced its results for the quarter ended March 31, 2026. EXHIBIT INDEX Exhibit Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed onits behalf by the undersigned, thereunto duly authorized. Date:June 18, 2026 Exhibit 99.1 Contact:Trinity Biotech plcPaul Murphy(353)-1-2769800 RedChip Companies Inc.Dave Gentry, CEO(1)-407-644-4256(1)-800-RED-CHIP (733-2447)TRIB@redchip.com Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results -Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets -Company publishes Q1 2026 financial results with revenue in line with prior guidance & substantial year-on-year grossmargin percentage improvements DUBLIN, Ireland (June 16, 2026) -Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused onhuman diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received additionalpurchase orders for over 2 million units of its flagship rapid HIV test, TrinScreen™ HIV. These orders are scheduled for fulfillment inQ3 2026 and are expected to make a meaningful contribution to the Company’s 2026 revenue and profitability objectives. These orders provide further evidence of renewed, broad-based demand for rapid HIV diagnostics across global health markets,following disruptions in 2025 due to changes affecting international aid funding structures. TrinScreenTMprograms in countries with high HIV prevalence, offering reliable results and ease of use in diverse clinical settings. These orders will be manufactured under the new offshored and outsourced manufacturing process, a key deliverable in the Company’s ComprehensiveTransformation Plan, which provides for efficient and cost-effective scalability. John Gillard, CEO of Trinity Biotech, commented: “Recent outbreaks of Ebola and Hantavirus serve as an important reminder of the ongoing public health risks posed by infectiousdiseases. Against this backdrop, these additional orders for TrinScreen HIV represent a further welcome indication of renewed focuson HIV disease management.” In addition, the Company continues to execute the commercial scale-up of outsourced upstream UniGold HIV™ production, followingregulatory approvals received earlier this year. This is a final core component in the Comprehensive Transformation Plan and uponscale-up completion is expected to deliver substantial improvements in gross margin, EBITDA and cashflow generation. TheCom